Ketogenic diet: an early option for epilepsy treatment, instead of a last choice only.
Level 5 - mechanism / opinion, no new human data
Narrative review and expert opinion without systematic review methodology or new human data.
PubMed 23515149 · doi:10.4103/2319-4170.107155
What was done
This is a narrative review and perspective summarizing clinical indications and international consensus guidance regarding the timing of ketogenic diet implementation in epilepsy management.
What was found
No quantitative data or statistical comparisons were reported in the abstract. The authors note that the ketogenic diet is required as first-line therapy for glucose transporter-1 deficiency and pyruvate dehydrogenase deficiency, appears effective in specific conditions like infantile spasms and Dravet syndrome, and should be considered earlier in epilepsy management while observing clear metabolic contraindications.
Why it matters
It argues for a clinical paradigm shift away from reserving ketogenic diets exclusively as a post-surgical or late-stage salvage option in epilepsy.
Limits
The abstract provides no primary human trial data, quantitative effect estimates, sample size, or systematic methodology to support comparative efficacy against standard antiepileptic drug regimens.
Cited by
- supports A ketogenic diet is medically contraindicated in patients with carnitine palmitoyltransferase deficiency (CPT-1 deficiency) and can be fatal.